Neoleukin Therapeutics (NLTX) Competitors

Pharming Group (NASDAQ:PHAR) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends, valuation and community ranking.

Does the media prefer PHAR or NLTX?

In the previous week, Pharming Group had 9 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 10 mentions for Pharming Group and 1 mentions for Neoleukin Therapeutics. Pharming Group's average media sentiment score of 0.63 beat Neoleukin Therapeutics' score of 0.00 indicating that Pharming Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharming Group	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neoleukin Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more risk & volatility, PHAR or NLTX?

Pharming Group has a beta of 0.02, suggesting that its stock price is 98% less volatile than the S&P 500. Comparatively, Neoleukin Therapeutics has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500.

Do institutionals & insiders have more ownership in PHAR or NLTX?

0.0% of Pharming Group shares are held by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are held by institutional investors. 2.1% of Pharming Group shares are held by company insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Do analysts rate PHAR or NLTX?

Pharming Group currently has a consensus price target of $30.00, suggesting a potential upside of 175.96%. Given Pharming Group's stronger consensus rating and higher probable upside, equities analysts clearly believe Pharming Group is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharming Group	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Does the MarketBeat Community prefer PHAR or NLTX?

Neoleukin Therapeutics received 27 more outperform votes than Pharming Group when rated by MarketBeat users. However, 67.65% of users gave Pharming Group an outperform vote while only 45.87% of users gave Neoleukin Therapeutics an outperform vote.

Company	Underperform	Outperform
Pharming Group	Outperform Votes 23 67.65%	Underperform Votes 11 32.35%
Neoleukin Therapeutics	Outperform Votes 50 45.87%	Underperform Votes 59 54.13%

Which has higher earnings & valuation, PHAR or NLTX?

Pharming Group has higher revenue and earnings than Neoleukin Therapeutics. Pharming Group is trading at a lower price-to-earnings ratio than Neoleukin Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharming Group	$320.71M	2.31	-$10.55M	-$0.20	-54.36
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	-6.56

Is PHAR or NLTX more profitable?

Neoleukin Therapeutics has a net margin of 0.00% compared to Pharming Group's net margin of -6.09%. Pharming Group's return on equity of -7.65% beat Neoleukin Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharming Group	-6.09%	-7.65%	-3.82%
Neoleukin Therapeutics	N/A	-37.22%	-30.91%

Summary

Pharming Group beats Neoleukin Therapeutics on 12 of the 17 factors compared between the two stocks.